UNSPSC 51263311: Quinazosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H23N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 436XK6QFMR, chemically known as 4-quinazolinamine, 6,7-dimethoxy-2-(4-(2-propenyl)-1-piperazinyl)- but generally known as quinazosin, which bears US NIH Compound Identifier 27486. European Medicines Agency schedules Quinazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10203MIG.

UNSPSC 51263311 Quinazosin is a Commodity code that captures pharmaceutical procurement for prescription medications and related health supplies. Recent state and local activity under this code shows government health and human services agencies buying naloxone (an opioid overdose reversal medication) and related drug deactivation systems, as well as engaging in market research around direct-to-manufacturer prescription fulfillment programs. The issuing bodies include county health departments and state health and human services commissions, which are seeking to establish reliable supply chains for emergency response medications and to explore cost-management strategies in pharmacy benefit administration.

Seminole County, Florida posted an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, and quarterly deliveries to the county community health building with all shipping included in the bid. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026, to gather vendor capabilities around direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling state-level interest in alternative procurement models for pharmaceutical supply. These two solicitations reflect activity concentrated in the Southeast and Texas, with government procurement focused on emergency response medications alongside exploration of innovative pharmacy contracting approaches.